January 2019—Qiagen launched its QIAscreen HPV PCR Test, a CE-marked in vitro molecular diagnostic test for the detection of 15 recognized high-risk genotypes of human papillomavirus.
Validated sample types include cervical specimens collected in PreservCyt, Pathtezt, and Surepath collection medium, as well as self-collected vaginal brush specimens collected and shipped dry or in saline or self-collected cervico-vaginal lavage specimens.
The test has been validated on Qiagen’s Rotor-Gene Q MDx system. The company also intends to offer a version of the test for NeuMoDx’s 96 and 288 molecular systems for customers who seek higher volume and fully integrated PCR-based HPV testing.
Qiagen, 800-426-8157